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A B S T R A C T
Background
Methadone maintenance was the first widely used opioid replacement therapy to treat heroin dependence, and it remains the best-
researched treatment for this problem. Despite the widespread use of methadone in maintenance treatment for opioid dependence in
many countries, it is a controversial treatment whose effectiveness has been disputed.
Objectives
To evaluate the effects of methadone maintenance treatment (MMT) compared with treatments that did not involve opioid replacement
therapy (i.e., detoxification, offer of drug-free rehabilitation, placebo medication, wait-list controls) for opioid dependence.
Search methods
We searched the following databases up to Dec 2008: the Cochrane Controlled Trials Register, EMBASE, PubMED, CINAHL,
Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug Council of Australia (ADCA) [www.adca.org.au],
Australian Drug Foundation (ADF-VIC) [www.adf.org.au], Centre for Education and Information on Drugs and Alcohol (CEIDA)
[www.ceida.net.au], Australian Bibliographic Network (ABN), and Library of Congress databases, available NIDAmonographs and the
College on Problems of Drug Dependence Inc. proceedings, the reference lists of all identified studies and published reviews; authors
of identified RCTs were asked about other published or unpublished relevant RCTs.
Selection criteria
All randomised controlled clinical trials of methadone maintenance therapy compared with either placebo maintenance or other non-
pharmacological therapy for the treatment of opioid dependence.
Data collection and analysis
Reviewers evaluated the papers separately and independently, rating methodological quality of sequence generation, concealment of
allocation and bias. Data were extracted independently for meta-analysis and double-entered.
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Main results
Eleven studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a
total number of 1969 participants. The sequence generation was inadequate in one study, adequate in five studies and unclear in
the remaining studies. The allocation of concealment was adequate in three studies and unclear in the remaining studies. Methadone
appeared statistically significantly more effective than non-pharmacological approaches in retaining patients in treatment and in the
suppression of heroin use as measured by self report and urine/hair analysis (6 RCTs, RR = 0.66 95%CI 0.56-0.78), but not statistically
different in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25) or mortality (4 RCTs, RR=0.48; 95%CI: 0.10-2.39).
Authors’ conclusions
Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment
and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant
superior effect on criminal activity or mortality.
P L A I N L A N G U A G E S U M M A R Y
Methadone maintenance therapy versus no opioid replacement therapy
Methadone maintenance treatment can keep people who are dependent on heroin in treatment programs and reduce their use of
heroin. Methadone is the most widely used replacement for heroin in medically-supported maintenance or detoxification programs.
Several non-drug detoxification and rehabilitation methods are also used to try and help people withdraw from heroin. However the
review found that people have withdrawn from trials when they are assigned to a drug-free program. Consequently, there are no trials
comparing methadone maintenance treatment with drug-free methods other than methadone placebo trials, or comparing methadone
maintenance with methadone for detoxification only. These trials show that methadone can reduce the use of heroin in dependent
people, and keep them in treatment programs.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Methadone maintenance treatment compared to No methadone maintenance treatment for opioid dependence
Patient or population: patients with opioid dependence
Settings: Prisons, hospitals, community based treatments and research facilities
Intervention: Methadone maintenance treatment
Comparison: No methadone maintenance treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No methadone mainte-
nance treatment
Methadone
maintenance treatment
Retention in treatment -
Old studies (pre 2000)
objective
Medium risk population RR 3.05
(1.75 to 5.35)
505
(3)
⊕⊕⊕⊕
high1,2
210 per 1000 640 per 1000
(368 to 1123)
Retention in treatment -
New studies
Medium risk population RR 4.44
(3.26 to 6.04)
750
(4)
⊕⊕⊕⊕
high2,3
154 per 1000 684 per 1000
(502 to 930)
Morphine positive urine
or hair analysis
objective
Medium risk population RR 0.66
(0.56 to 0.78)
1129
(6)
⊕⊕⊕⊕
high
701 per 1000 463 per 1000
(393 to 547)
Criminal activity
objective
Medium risk population RR 0.39
(0.12 to 1.25)
363
(3)
⊕⊕⊕©
moderate4
118 per 1000 46 per 1000
(14 to 148)
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Mortality
objective
Medium risk population RR 0.48
(0.1 to 2.39)
576
(4)
⊕⊕⊕©
moderate4
17 per 1000 8 per 1000
(2 to 41)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidance
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 RR 3.05
2 Other Cochrane review showing dose related effect : Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at
different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD002208. DOI: 10.1002/
14651858.CD002208
3 RR 4.4
4 Too few numbers of events observed
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B A C K G R O U N D
Description of the intervention
Currently, the major form of medical therapy for heroin depen-
dence internationally involves orally administered methadone.
Methadone is an analgesic medication developed to treat pain in
the 1940s. It has been, and is still, prescribed widely for the man-
agement of pain in America, Australia and Europe.
It was in New York in the 1960s, during an increase in heroin
use and heroin dependence, that researchers (Dole 1965; Dole
Nyswander 1967) examined different prescribed opioids to man-
age heroin dependence, and reported that they found that metha-
done was most suitable to the task. They believed that long-term
heroin use caused a permanent metabolic deficiency in the central
nervous system and an associated physiological disease, which re-
quired regular administration of opiates to correct the metabolic
deficiency (Dole Nyswander 1967). The disorder of opioid de-
pendence has been represented in the International Classification
of Disease of the World Health Organisation. It is a chronic or
long-term and relapsing disorder, and some believe that it requires
ongoing maintenance medication.
How the intervention might work
The aspects of methadone that have led to its use as a substi-
tute drug for heroin include the number of pharmacological fea-
tures of opioids. At the basis of methadonemaintenance treatment
(MMT) is the observation that opioid analgesics can be substi-
tuted for one another (Jaffe 1990). Methadone at adequate doses
(of 20mg to more than 100 mg) prevents or reverses withdrawal
symptoms (Ward 1992), and thus reduces the need to use ille-
gal heroin (Jaffe 1990). Methadone remains effective for approx-
imately 24 hours, requiring a single daily dose rather than the
more frequent administration of three to four times daily which
occurs with the shorter-acting heroin (Jaffe 1990).Methadone can
“block” the euphoric effects of heroin, discouraging illicit use and
thereby relieving the user of the need or desire to seek heroin (Dole
1969). This allows the opportunity to engage in normative activi-
ties, and “rehabilitation” if necessary. Methadone can cause death
in overdosage, like other similar medications such as morphine,
and for this reason it is a treatment which is dispensed under med-
ical supervision and relatively strict rules. In summary, methadone
is a long-acting opioid analgesic with well-understood pharmaco-
logical characteristics which make it suitable for stabilising opioid
dependent patients in a maintenance treatment approach.
There is evidence that the quality of the therapeutic relationship
with staff in methadone clinics plus the intensity of these ancillary
services, combined with the dose of methadone prescribed will
all act to enhance the outcome for methadone treatment (Ward
1992), although this is not the focus of this review.
Why it is important to do this review
Methadone maintenance treatment remains one of the best
researched treatments for opioid dependence (Cooper 1983;
Gerstein 1990; Hargreaves 1983; Mattick 1993; Ward 1992). It is
the only treatment for opioid dependence which has been clearly
demonstrated to reduce illicit opiate use more than either no-
treatment (Dole 1969; Yancovitz 1991; Dolan 2003; Schwartz
2006, Kinlock 2007), drug-free treatment (Gunne 1981), placebo
medication (Newman 1979; Strain 1993a), or detoxification
(Vanichseni 1991; Gruber 2008; Sees 2000) in clinical controlled
trials. These trials have been conducted by different research
groups, in markedly differing cultural settings, yet have converged
to provide similar results.
O B J E C T I V E S
The present systematic review aimed to provide an evaluation of
the effectiveness of methadone maintenance treatment on opioid
dependence compared with treatments that did not include an
opioid replacement therapy. The focus of the review is on retention
in treatment, opioid use as measured by objective urine results and
from self-report, as well as criminal activity and patient mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The literature was reviewed for all clinical controlled trials of
MMT against another treatment which does not use opioid re-
placement therapy.
Types of participants
Individuals who were opioid dependent were the target popula-
tion for this review. No distinction was made between those using
heroin and those who have been in methadone treatment prior to
entering the research trial treatment. No restrictions were imposed
in terms of studies of outpatients, inpatients, those with comorbid
states, etc.
Types of interventions
Interventions were included if they used methadone maintenance
therapy (MMT). The MMT interventions were included even
where they also employed other treatments, such as behavioural
therapies or outpatient rehabilitation. The control groups were
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treated with placebo medication, withdrawal or detoxification
(with or without ancillary medication), drug-free rehabilitation
treatment (such as therapeutic communities), and no treatment
or wait-list controls.
Types of outcome measures
Primary outcomes
1. retention in treatment
2. mortality
3. proportion of urine or hair analysis results positive for
heroin (or morphine)
4. self-reported heroin use
5. criminal activity
Secondary outcomes
1. use of other drugs
2. physical health
3. psychological health
Search methods for identification of studies
Electronic searches
1.Cochrane Central Register of Controlled Trials, which includes
the Cochrane Drugs and Alcohol Group Register of Trials (CEN-
TRAL - The Cochrane Library issue 4, 2008)
2.PubMed (January 2001 - December 2008)
3.Embase (January 2001- December 2008)
4.CINAHL (January 2001 - December 2008)
For details on searches see Appendix 1; Appendix 2; Appendix 3;
Appendix 4
The search strategy was developed in consultation with a drug and
alcohol research information specialist.
Searching other resources
1. Some of the main electronic sources of ongoing trials
(National Research Register, meta-Register of Controlled Trials;
Clinical Trials.gov, Agenzia Italiana del Farmaco)
2. Conference proceedings likely to contain trials relevant to
the review (College on Problems of Drug Dependence - CPDD)
3. Library of Congress databases were also searched for studies
and book chapters with the key terms: methadone, clinical trial,
and randomised control trial.
4. National focal points for drug research (e.g., National
Institute of Drug Abuse (NIDA), National Drug & Alcohol
Research Centre (NDARC))
5. Reference lists of all relevant papers to identify further
studies.
6. Authors of identified RCT’s were consulted to find out if
there were any other published or unpublished RCT’s comparing
the efficacy of methadone maintenance vs against another
treatment which does not use opioid replacement therapy.
7. As several drug and alcohol journals are not indexed on the
main electronic databases, the following databases were searched
up until December 2008:
• “Current Contents
• ”Psychlit
• “CORK [www. state.vt.su/adap/cork]
• ”Alcohol and Drug Council of Australia (ADCA)
[www.adca.org.au]
• “Australian Drug Foundation (ADF -VIC)
[www.adf.org.au]
• ”Centre for Education and Information on Drugs and
Alcohol (CEIDA) [www.ceida.net.au]
• “Australian Bibliographic Network (ABN).
All searches included non-English language literature and studies
with English abstracts were assessed for inclusion. When
considered likely tomeet inclusion criteria, studies were translated.
Data collection and analysis
Selection of studies
Each potentially relevant study located in the search was obtained
and independently assessed for inclusion by two of three reviewers.
Data extraction for each study was undertaken by the same two
reviewers, again independently.
Data extraction and management
Each potentially relevant study located in the search was obtained
and independently assessed for inclusion by two of three review-
ers. Data extraction for each study was undertaken by the same
two reviewers, again independently. A standardised checklist was
used for data extraction. Disagreement was dealt with by the third
reviewer, acting as a mediator. If unresolved disagreements on in-
clusion, study quality or extraction occurred they were referred to
the editor.
Assessment of risk of bias in included studies
Due the type of comparisons analysed (MMT versus methadone
detoxification or waiting list), blinding is often difficult to apply.
As such, methodological quality was assessed by assessment of the
randomisation procedure and the likelihood that randomisation
was not biased:
A. Low risk of bias (allocation clearly independent of clinical staff );
B. Moderate risk of bias (some doubt about the independence of
the allocation procedure); and
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C.High risk of bias (inadequate separation of randomisation from
clinical staff ).
Measures of treatment effect
A standardised effect size was calculated for each study, based on
themain outcomemeasure reported.Where possible (relative risks
and 95% confidence intervals for dichotomous outcomes (reten-
tion) using a random effects model and standardised mean dif-
ferences for continuous outcomes were presented. To assess for
statistical heterogeneity a test of homogeneity was undertaken. A
pooled effect size estimate was derived for each domain of mea-
surement (retention in treatment, urine analysis results for heroin/
morphine ), self-reported heroin use, and criminal activity. The
retention in treatment and urine results were reported as the num-
ber of patients retained or the number with a morphine-positive
urine result at follow-up, a form of reporting that allowed for di-
chotomous analysis of those data.
Data synthesis
The results were integrated from the meta-analytic review into a
discussion taking into consideration other publications including
large-scale observational studies, studies of the pharmacology of
methadone, and studies of the effect of MMT on HIV serocon-
version. Convergence of the evidence from the meta-analysis and
the narrative review was taken to indicate a robust conclusion.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We considered fourteen studies for inclusion, three were ex-
cluded because they did not satisfy the inclusion criteria (see
Characteristics of excluded studies table) and elevenwere included
(Characteristics of included studies Charachteristics table) with a
total of 1969 participants.
Included studies
Eleven studieswere included in this review.Refer toCharacteristics
of included studies Table for more detailed information.
Treatment regimes and settings
The first study by Dole (Dole 1969) was a two group randomised
trial where patients either receivedmethadone or placed on a wait-
list. The study by Gunne (Gunne 1981) randomly allocated pa-
tients to receive methadone maintenance or to be allocated to a
drug-free rehabilitation. None of the patients allocated to drug-
free rehabilitation took up the offer, refusing treatment after they
had learnt that theywould not receive methadone. There were two
placebo controlled trials (Newman 1979, Strain 1993a). Finally,
there have been six randomised clinical trials, three assessing meth-
adone maintenance against methadone detoxification (Vanichseni
1991, Sees 2000, Gruber 2008) and the others assessing meth-
adone maintenance against a wait-list control (Yancovitz 1991,
Dolan 2003, Schwartz 2006).
Three studies were conducted in a prison setting (Dole 1969,
Dolan 2003, Kinlock 2007). The remainder were conducted in
medical or research facilities.
The sample sizes in these studies were sometimes small, in that
two studies having sample sizes of 32 and 34 (Dole 1969, Gunne
1981), respectively. The remaining seven studies had sample sizes
ranging from 100 to 240 (Newman 1979, Vanichseni 1991, Sees
2000, Gruber 2008) patients up to 247 to 382 patients (Strain
1993a, Yancovitz 1991, Dolan 2003, Schwartz 2006).
The dosages of methadone used in these studies appears to have
been adequate. In the first study, (Dole 1969) the dose at release
from prison was 35 milligrams but patients were entered into a
community program where blockade doses of approximately 100
milligrams were standard. In the study by Gunne (Gunne 1981)
the doses are not clearly stated. The placebo-controlled study by
Newman (Newman 1979) have an average dose on 97 milligrams
per day. An average of 74 milligrams per day was reported in the
study from Thailand (Vanichseni 1991). Strain (Strain 1993a)
used doses of methadone of 50 and 20 milligrams per day. The
study by Dolan (Dolan 2003) had a mean methadone dose of
61mg. The study by Schwartz (Schwartz 2006) had a mean dose
of 78.4mg and Sees (Sees 2000) had a mean methadone dose of
86.3mg. The study by Gruber (Gruber 2008) used a methadone
dose range of 60-90mg and Kinlock (Kinlock 2007) set a target
dose of 60mg. Finally, the study by Yancovitz (Yancovitz 1991)
used a maintenance dose of approximately 80 milligrams per day.
As such, the results from the studies appear to use moderate to
high doses on average.
Duration of the trials
As shown in the table of included studies, the interventions gen-
erally lasted for significant time of several weeks up to two years,
although one study only ran 45 days (Vanichseni 1991).
Countries in which the studies were conducted
The studies were conducted in a range of countries including;USA
(Dole 1969, Yancovitz 1991, Strain 1993a, Sees 2000, Schwartz
2006, Gruber 2008), Sweden Gunne 1981), Australia (Dolan
2003), Hong Kong (Newman 1979) and Thailand (Vanichseni
1991).
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Participants
The participants (N=1969) were largely typical of heroin depen-
dant individuals, in terms of age and gender characteristics. In
some studies, only males were included but where females were
included the gender distribution was as one would expect, with
majority of the participants beingmale. They tended to be approx-
imately 30 to 40 years of age, often unemployed and unmarried,
with previous treatment histories and prevalence of use of other
drugs, consistent with what is known about heroin users present-
ing for treatment.
Types of comparisons
The review compared methadone maintenance treatment with no
methadone maintenance treatment. All studies were assessed to
determine whether they provided data on retention in treatment,
codeable results from urine/hair analysis, self-reported drug use
(particularly heroin use), criminal activity and mortality. After
reviewing the studies, it was realised that it was not possible to
include urine/hair results for cocaine and benzodiazepines as these
were not reported in an analysable form for most studies. It was
not possible to analyse data on either cocaine or benzodiazepine
positive urines from these studies. However, it was possible to code
data on retention in treatment, morphine positive urine or hair
analysis, self-reported heroin use, criminal activity and mortality.
Excluded studies
Three studies were not included. Refer to the Characteristics of
excluded studies for the reason for exclusion.
Risk of bias in included studies
Allocation
The study conducted by Dole (Dole 1969) had inadequate se-
quence generation for randomisation and was unclear on the con-
cealment of allocation.The studies conducted by Sees 2000,Dolan
2003, Schwartz 2006, Gruber 2008 and Kinlock 2007 had ade-
quate sequence generation for randomisation. The study byDolan
2003 also had adequate concealment of allocation, as did the stud-
ies by Yancovitz 1991 and Newman 1979. It was unclear if the
remaining studies had adequate sequence generation and conceal-
ment of allocation.
Blinding
Of the eleven studies included in this review, two were placebo-
controlled trials (Newman 1979, Strain 1993a). Both of these
studies were double-blind but Strain 1993a did not provide suf-
ficient data to be confident about the concealment of allocation.
The remaining studies were not blinded.
Incomplete outcome data
All studies addressed the issue of incomplete outcome data ade-
quately and were independently deemed by reviewers to be free of
other major bias (Figure 1; Figure 2).
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Effects of interventions
See: Summary of findings for the main comparison
Results of meta-analyses
Comparison 01 Methadone maintenance treatment versus
no methadone maintenance treatment
1.1 Retention in treatment:
7 studies; 1287 participants (Gruber 2008, Kinlock 2007,
Newman 1979, Schwartz 2006, Sees 2000, Strain 1993a,
Vanichseni 1991). The relative risk on a random effect model
was applied. The chi-square test for heterogeneity was significant
(p<0001) so a pooled estimate is not reported. However, the re-
sults from all studies showed that methadone has a superior reten-
tion rate compared with control conditions.Subgroup analysis was
conducted examining the older studies (pre 2000) and the more
recent studies, as differences in results can occur over time. The
heterogeneity for the older studies (Newman 1979, Strain 1993a,
Vanichseni 1991; 3 studies, 505 patients) was significant, as in-
dicated in the previous published review. (Analysis 1.1.1). Data
from the newer studies (Gruber 2008, Kinlock 2007, Schwartz
2006, Sees 2000) show the superiority of methadone over control
in retaining patients in treatment (4 studies, 750 patients, RR=
4.44, 95% CI:3.26-2.04). The test for heterogeneity was not sig-
nificant (Analysis 1.1.2).
1.2 Morphine positive urine or hair analysis
6 studies, 1129 participants (Dolan 2003, Gruber 2008, Kinlock
2007, Schwartz 2006, Vanichseni 1991, Yancovitz 1991). Turning
to the data frommorphine positive urine/ hair analysis, five studies
(Vanichseni 1991, Yancovitz 1991, Dolan 2003, Schwartz 2006,
Gruber 2008) provided dichotomous data as to whether patients
had morphine positive urine/hair at follow up. The results from
these studies providing data on the presence/absence of morphine
in urine at the follow-up showed an advantage ofmethadone above
the control conditions (6 studies, 1129 patients RR = 0.66, 95%
CI 0.56-0.78), in this case detoxification, wait-list or control, in
reducing heroin use as shown by a lack of heroin metabolites in
urine or hair. (Analysis 1.2)
1.3 Self-reported heroin use
6 studies, 682 participants (Dolan 2003,Dole 1969,Gruber 2008,
Gunne 1981, Kinlock 2007, Vanichseni 1991). The results from
the objective data on morphine positive urine/hair analysis were
also supported by self-report data from five studies. In particular,
studies from the USA, Sweden and Australia (Dole 1969, Gunne
1981, Yancovitz 1991, Dolan 2003, Kinlock 2007) all concurred
to show an advantage for methadone above control in reduction of
heroin use as reported by the patients. The study by Gruber 2008
showed no difference between groups. The test for heterogeneity
was significant (p<0.000001) so a pooled estimate is not reported.
(Analysis 1.3)
1.4 Criminal activity
3 studies, 363 participants (Dole 1969, Gunne 1981, Yancovitz
1991). The results for the criminal activity variable, available for
three studies, were consistent with the reduction in heroin use,
even though the advantage for methadone beyond control in re-
ducing criminal activity was not statistically significant (3 studies,
363 patients RR=0.39, 95% CI:0.12-1.25). The test for hetero-
geneity was not significant. (Analysis 1.4)
1.5 Mortality
4 studies, 576 participants (Gunne 1981, Kinlock 2007, Newman
1979, Yancovitz 1991). Turning finally to the evidence concern-
ing the ability of methadone to prevent deaths, available for four
studies, the results showed a trend in favour of methadone that
was not statistically significant (4 studies, 576 patients RR=0.48,
95% CI: 0.10-2.39). (Analysis 1.5)
Other measures (e.g., use of other drugs, physical health, and psy-
chological health) are too infrequently and irregularly reported in
the literature to be usefully integrated in the quantitative review.
The results are also summarized in the Summary of findings table
1
D I S C U S S I O N
Summary of main results
The results of the meta-analysis indicate that methadone is able to
retain patients in treatment better than the drug-free alternatives
(placebo medication, offer of drug-free treatment, detoxification,
or wait-list control), to suppress heroin use based on morphine
(the heroin metabolite) found in urine/hair samples, and patient
self-report. There was a greater reduction in criminal activity and
mortality among the MMT patients, but these differences were
not statistically significant. There is evidence from other literature
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showing mortality (Gibson 2008, Clausen 2008) and criminal
activity (Lind 2005) is decreased in patients who are inmethadone
treatment.
Overall completeness and applicability of
evidence
Interestingly, the results from these eleven randomised trials all
showed statistically significant positive benefits from methadone
treatment, despite their small sample sizes. Additional support for
the efficacy of methadone maintenance treatment comes from the
results of many observational studies wherein some statistical form
of control has addressed alternative explanations of apparent ef-
fectiveness. These large scale observational studies have generally
supported the results from the randomised clinical trials in show-
ing that methadone maintenance treatment reduces the use of
heroin and decreases criminal activity (Ward 1998). As noted ear-
lier there is a broader international literature showing advantages
for methadone beyond other treatments in terms of reduction of
death (Ward 1998), even though the randomised trial data do not
show this result.
Another relevant outcome to be considered would be serocon-
version for HIV, which is the object of a separate Cochrane re-
view (Gowing 2004).Methadonemaintenance treatment has been
shown to reduce HIV risk taking behaviour (specifically reduc-
tion in needle sharing) and thereby has achieved a reduction in
the transmission of HIV. Consistent with this it has been shown
that methadone maintenance treatment is protective of patients,
reducing HIV infection in geographic locations where HIV had
spread rapidly among injecting drug users who had not entered
treatment. We have commented elsewhere on two large prospec-
tive cohort studies in the USA which found methadone mainte-
nance treatment protected against HIV infection (Ward 1998).
This outcome could not be addressed here as there are no ran-
domised trials of methadone that have included HIV status as a
measure, the evidence coming from observational studies.
Quality of the evidence
It is notable that the doses of methadone used in the randomised
clinical trials are probably slightly higher than are being used cur-
rently in routine clinical practice in some parts of the world. This
relative underdosing in clinical practice may lead to a reduction
in the effectiveness of methadone, as the response to methadone
treatment is dose-dependent. In addition, it is important to recog-
nise that methadone treatment in these trials was often provided
with substantial ancillary services. These ancillary services have
included counselling, psycho-social services, medical services and
often psychiatric care. The quality of the therapeutic relationship
with staff in methadone clinics plus the intensity of these ancillary
services, combined with the dose of methadone prescribed will all
act to enhance the outcome for methadone treatment. The extent
that clinical programs move away from such an approach might
be expected to impact on the effectiveness of methadone.
This does not imply that methadone maintenance treatment will
become ineffective. Even allowing for some reduction in effective-
ness when methadone is not provided in the fashion that it has
been in the clinical trials, it is still likely to be effective. The ef-
fects of methadone may be modest, if they are judged by unrealis-
tic expectations of patients can easily achieve enduring abstinence
from opioid drugs. Methadone nonetheless attracts and retains
more patients than alternative treatments, and it does produce
better outcomes amongst those who complete treatment. Metha-
done maintenance appears to provide better outcomes than simple
detoxification programs, where the evidence suggests that short-
term detoxification has no enduring effect on drug use (Mattick
1996).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The implications of the results of the meta-analytic review con-
ducted and reported herein for clinical practice are that metha-
done maintenance treatment is an effective intervention for the
management of heroin dependence. Methadone retains patients
in treatment and reduces heroin use. Methadone should be sup-
ported as a maintenance treatment for heroin dependence.
Implications for research
Overall there are a relatively limited number of randomised clin-
ical trials on the efficacy of methadone treatment compared to
placebo. It does not seem feasible at this stage to conduct further
randomised trials of methadone treatment. However, evidence on
reduction of criminal activity and mortality from clinical trials is
lacking calling for an additional systematic review of observational
studies. Moreover, monitoring of the outcome of standard metha-
done treatment in clinical practice may be important as a research
activity to demonstrate its ongoing effectiveness, or to determine
whether its effectiveness is being compromised through the reduc-
tion of ancillary services or reduction in adequate dose levels.
A number of measures (e.g., of other drug use, physical health,
and psychological health) were too infrequently and irregularly re-
ported in the literature to be usefully integrated in the quantitative
review, but future research might address these important areas.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dolan 2003
Methods Two group, open, randomised controlled trial. Randomisation: in blocks of ten by ran-
domly drawing cards from an envelope. List of case numbers and group allocation not
known to researcher or trial nurse. Follow up for four months
Participants Geographic region: Australia
Study setting: Prison. Participants were inmates on a waiting list for MMT
n = 382 males
mean age = 27 years
Eligibility criteria: heroin problem confirmed by medical interview, serving sentences of
more than four months, and able to provide informed consent
Interventions Treatment: methadone maintenance treatment - flexible dose (mean 61mg, range 1-
180mg).
Control: wait-list.
Outcomes Heroin use -Hair analysis and self report. Syringe sharing. HIV andHCV seroprevalence
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Drawing lots.
Allocation concealment? Yes A-Adequate. Central allocation.
Incomplete outcome data addressed?
All outcomes
Yes Missing outcome information balanced be-
tween groups. 191 randomised to each
group, 124 and 129 followed up in each
group
Free of other bias? Yes Baseline characteristics similar.
Dole 1969
Methods Two group, open, randomised controlled trial. Randomisation: release dates of treatment
applicants were selected by lottery. Applicants who were not selected and demonstrated
motivation for treatment became untreated controls. Follow-up for 50 weeks
Participants Geographic region: USA
Study setting: Prison. Participants were inmates eligible for release over a four month
period from New York City Correctional Institute for Men.
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Dole 1969 (Continued)
n = 32 males
mean age = 30 years
15% European descent, 10% African American, 7% Hispanic
Eligibility criteria: heroin dependence for 5 or more years, record of 5 or more previous
convictions, not committed to custody of Addiction Services Agency
Interventions Control: wait-list
Treatment: 10 day methadone maintenance pre-release.
Initial dose 10 mg, increasing to 35 mg at release.
Continued methadone maintenance in outpatient clinic after release
Outcomes Urinalysis (weekly for heroin, amphetamines, cocaine, barbituates and alcohol)
Employment / education
Reincarceration
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Used release dates in a lottery.
Allocation concealment? Unclear B- Unclear. Concealment of allocation not
specified.
Incomplete outcome data addressed?
All outcomes
Yes No missing data.
Free of other bias? Yes
Gruber 2008
Methods Three group randomised controlled trial. Randomisation: generated by statistician who
placed assignments in sealed envelopes not revelaed to project staff. Allocation to group
(21 day methadone detoxification, 6 months methadone with minimal counselling or 6
monthsmethadonewith standard couselling) revealed at conclusion of baseline interview
Participants Geographic region: USA
Study setting Outpatient hospital detoxification program.
n=111, 68% male
mean age=41.9 years
54% White, 30% African American, 20% Hispanic, 4% Native American, 5% Asian/
Pacific Islander
85% unmarried
Eligibility criteria; latent TB infection, DSM III R opioid dependence, aged 21-59, and
willingness to receive isonaid preventive therapy and MMT. Excluded if pregnant or
HIV positive or active liver disease
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Gruber 2008 (Continued)
Interventions Treatment: 6 months methadone maintenance with minimal or standard counselling,
followed by 6 week taper. Control: 21 day methadone detoxification
Outcomes Retention
Illicit drug use - self report and urinalysis (monthly)
Notes Results from the standard counseling and minimal counseling groups have been com-
bined and compared to the detoxification group
Unpublished data - the author provided additional data to enable the coding of retention
and heroin use
All participants have active TB infection - study part of a larger study examining TB
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”generated by a statistician“.
Allocation concealment? Unclear B - Unclear. Individual sealed envelope not
revealed to project staff. Does not state
opaque
Incomplete outcome data addressed?
All outcomes
Yes 4 in detox group in MMT elsewhere
Free of other bias? Yes At baseline standard MMT group younger
and detox group had more depressive
symptoms
Gunne 1981
Methods Two group randomised clinical trial. Randomisation: after eligibility established subjects
were randomly allocated to methadone maintenance or to drug-free treatment. Foow up
for two years
Participants Geographic region: Sweden
Study setting: psychiatric research centre
n = 34, 76% male
Eligibility criteria: 20-24 years, history of at least 4 years IV heroin use, withdrawal signs
and positive urine on admission, a minimum of three completed detoxifications, not
arrested or serving a sentence and no dominate abuse of non-opiate drugs. Exclusion:
active infectious disease
Interventions Control: no treatment, could not apply for the methadone program for two years.
Treatment: methadone maintenance treatment, no dosage information reported
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Gunne 1981 (Continued)
Outcomes Illicit drug use / Urinalysis (3 x week)
Criminality
Vocational adjustment
Health
Mortality
Notes 2 controls obtained methadone from private practitioners and were excluded
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ”Randomly allocated“
Allocation concealment? Unclear B - Unclear
Incomplete outcome data addressed?
All outcomes
Yes No missing data. All controls refused drug
free treatment and asked for discharge
Free of other bias? Yes Only indiv 20-24. Baseline groups similar
except gender - more women in MMT
Kinlock 2007
Methods Three group randomised controlled trial. Randomisation: after eligibility established
subjects were randomly allocated to one of three groups. Randomisation process not
described. Follow up for one month
Participants Geographic region: USA
Study setting: Prison. Participants were inmates due for release in 3-6 months
n = 211 males
mean age =40.3 years
70% African American, 24% Caucasian
Eligibility criteria: DSM IV heroin dependence at time of incarceration, suitability for
MMT as determined by medical assessment, willingness to enrol in prison MMT and
residing in Baltimore on release. Individuals that did not meet dependence criteria were
eligible if they had been enrolled in an opiate treatment program the year prior to
incarceration
Interventions Treatment: Counseling and methadone maintenance in prison with transfer into treat-
ment on release. Target methadone dose 60mg
Control: Counseling in prison with passive referal to treatment upon release
Outcomes Entry into community MMT
Illicit drug use - self report and urinalysis
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Kinlock 2007 (Continued)
Notes A third group received counseling in prison and active referal to MMT on release group.
These results have not been included in the analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Block randomisation procedure.
Allocation concealment? Unclear B- Unclear. Not specified.
Incomplete outcome data addressed?
All outcomes
Yes No missing data. Report ITT
Free of other bias? Yes No differences between group at baseline.
Newman 1979
Methods Double blind randomised clinical trial
Randomisation: subjects randomly allocated on discharge from hospital after 2 week
stabilisation on 60mg methadone to detoxification or continued maintenance
Participants Geographic region: Hong Kong
Study setting: Hospital and outpatient clinic
n = 100 males
mean age = 38 years
Eligibility criteria: male, 22-58 years, history of heroin dependence for at least 4 years and
at least one previous treatment, current heroin dependence by three consecutive positive
urine samples, voluntary application for admission (criminal justice referrals excluded),
resident with fixed address, absence of past or present major psychiatric or medical illness
Interventions Treatment: methadone maintenance - flexible dose (average 97 mg / day).
Control: detoxification from60mgmethadone at 1mg/day for 60 days, placebo thereafter
Outcomes Illicit drug use / Urinalysis (daily collection, analysed 2 x week for morphine only)
Retention
Criminal activity
Mortality
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomly assigned’
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Newman 1979 (Continued)
Allocation concealment? Yes A - Adequate ’neither patients nor clinic
staff knew which group’ ’pharmacist only
staff aware’
Incomplete outcome data addressed?
All outcomes
Yes No missing data. Report ITT.
Free of other bias? Yes No difference between group at baseline
Schwartz 2006
Methods Two group randomised controlled trial with participants randomised to interim meth-
adone maintenance treatment or a wait list control. Random assignment generated by
random number table and sealed in an envelope
Participants Geographic region: USA
Study setting: community methadone treatment facility.
n=319, 59% male
mean age =41.4 years
93% African American
62% unemployed
Eligibility criteria; DSM IV heroin dependence and informed consent. Exclusions; preg-
nant or acute medical or psychiatric illness
Interventions Treatment: interim methadone maintenance treatment for 120 days after which entry
into a comprehensive methadone treatment program if unable to gain entry before 120
days
Control: wait-list
Outcomes Entry into comprehensive methadone maintenance treatment at 4 months.
Illicit drug use /self report and urinalysis. Criminal activity
Notes Mobile program that at time of study administered methadone from specially equipped
recreational vehicle
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’table of random numbers’
Allocation concealment? Unclear B - Unclear. Sealed envelope but unclear if
opaque and sequentially numbered
Incomplete outcome data addressed?
All outcomes
Yes Missing outcome information balanced be-
tween groups. 95% MMT and 89% wait
list located for follow up
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Schwartz 2006 (Continued)
Free of other bias? Yes No difference between group at baseline
Sees 2000
Methods Two group randomised controlled trial. Randomisation: participants randomly allocated
from stratified blocks to methadone maintenance treatment or 180-day methadone
assisted detoxification
Participants Geographic region: USA
Study setting: Medical Center
n=179, 59% male
mean age = 39.4 years
52% Caucasian, 30% African American, 13% Hispanic
53% unemployed, 79% unmarried
Eligibility criteria: opioid depeendent and urine screen positive for opioid and negative
for methadone
Interventions Treatment:methadonemaintenance for 14months followedby a 2month detoxification.
Participants required to attend 1hr/wk group therapy and 1hr/wk individual theray for
first 6 months.
Flexible dose (max dose of 100mg/d)
Control: 14 months of substance abuse treatment. 120 days induction and methadone
maintenance followed by 60 days of dose reductions. Participants were required to attend
2hr/wk group therapy, 1hr /week education classes and weekly individal therapy sessions.
During month 7-14 participants offered nonmethadone aftercare treatment - group and
individual therapy and liaison services with criminal justice, medical clinics and social
services
Outcomes Retention
Illicit drug use - self report and monthly urinalysis.
HIV risk behaviours
Notes Retention data was taken at 180 days from Fig 3 in the published paper
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’generated via computer software by statis-
tician using various block sizes’
Allocation concealment? Unclear B - Unclear ’kept in sealed envelope’. Un-
clear if opaque and sequentially numbered
Incomplete outcome data addressed?
All outcomes
Yes Missing outcome information balanced be-
tween group.
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Sees 2000 (Continued)
Free of other bias? Yes No differences between group at baseline.
Strain 1993a
Methods Three group, double-blind, placebo controlled randomised controlled trial. Patients were
stratified by race and sex and randomly assigned to a fixed dose schedule at admission.
Treatment group assignment, stabilisation dose and dosing schedules were blind to pa-
tient and clinic staff with patient contact
Participants Geographic region: USA
Study setting: methadone treatment research clinic
n = 247, 70% male
mean age = 34 years
50% African American
62% unemployed, 84% unmarried
Eligibility criteria: 18-50 years, history of IV opioid dependence, no chronic medical
illness, absence of major mental illness, negative pregnancy test and at least three months
since last treatment at the clinic
Interventions Initial treatment of active methadone for at least 5 weeks.
15 weeks of stable dosing at 50, 20 or 0 mg per day
Gradual tapering for those receiveing active methadone from weeks 21-26
Individual counselling and group therapy (weekly).
Outcomes Retention
Treatment compliance
Illicit drug use / Urinalysis (collected 3 x weekly, one sample selected at random for
analysis for opioids, cocaine and benzodiazepines)
Notes A subsample of 0mg patients (n=44) received an 8 week induction, reaching 0mg at 9
weeks. Data for patients in alternate 0mg treatment groups are collapsed
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’randomly assigned’ stratified by race and
sex. Unclear not enough information
Allocation concealment? Unclear B - Unclear
Incomplete outcome data addressed?
All outcomes
Yes
Free of other bias? Yes Baseline groups similar.
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Vanichseni 1991
Methods Two group, open label, randomised clinical trial, with participants who applied for 45
daymethadone detoxification and had at least six prior treatment episodes were randomly
assigned to methadone maintenance or detoxification
Participants Geographic region: Thailand
Study setting: narcotics clinic
n = 240 males
30% unemployed, 52% unmarried
Eligibility criteria: heroin injectors applying for 45-day detoxification, at least 6 prior
treatment episodes at the clinic
Interventions Treatment: methadone maintenance (flexible dose, average 74mg)
Control: standard 45 day methadone detoxification
Outcomes Retention
Illicit drug use
Urinalysis (2 x week for opiates)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear. Not enough information pro-
vided.
Allocation concealment? Unclear B - Unclear
Incomplete outcome data addressed?
All outcomes
Yes Urine provided for drop outs.
Free of other bias? Yes
Yancovitz 1991
Methods Two group randomised clinical trial, with opioid dependent participants on waiting-lists
for comprehensive methadone maintenance programs who were randomised to either
the interim methadone program or wait list with frequent contact
Participants Geographic region: USA
Study setting: interim methadone clinic
n = 301, 79.4% male
55% Hispanic, 35% African American, 10% White
86% unemployed
Eligibilty criteria: wait list for comprehensive methadone maintenance program
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Yancovitz 1991 (Continued)
Interventions Control: wait-list with frequent contact
Treatment: ”interim“ methadone maintenance; standard physical exam on admission,
flexible dosing 5 days a week, pick up on weekends from another site, minimal coun-
selling, referral to community agencies
Outcomes Urinalysis (2 x weekly for heroin and cocaine)
Entry into conventional treatment
Notes For the first 3 months of the study there were three experimental groups; interim meth-
adone, wait-list with frequent contact and bi-weekly urinalysis, and the wait-list with
no contact. Recruitment slowed which resulted in the protocol being changed two ex-
perimental groups; interim methadone and wait-list with frequent contact. The wait-list
then only lasted one month at which time the participants were switched to a methadone
program.
Data from the initial discontinued minimal contact group is not include in the analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’randomly assigned’. Not enough informa-
tion
Allocation concealment? Yes A - Adequate. ’assigned by administrative
staff at another location’
Incomplete outcome data addressed?
All outcomes
Yes Missing outcome information balanced be-
tween group. Follow up 50% inMMT and
36% for control
Free of other bias? Yes No baseline differences.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bale 1980 The authors planned to conduct a randomised controlled trial comparing methadone maintenance, therapeutic
communities and detoxification programs. Ethical and practical problems prevented random assignment and the
study therefore does not meet inclusion criteria for this review
Dolan 2005 This paper presents follow up results from the study reported in Dolan 2003
Schwartz 2007 This paper presents follow up results from the study reported in Schwartz 2006
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D A T A A N D A N A L Y S E S
Comparison 1. Methadone maintenance treatment vs No methadone maintenance treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Retention in treatment 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Old studies (pre 2000) 3 505 Risk Ratio (M-H, Random, 95% CI) 3.05 [1.75, 5.35]
1.2 New studies 4 750 Risk Ratio (M-H, Random, 95% CI) 4.44 [3.26, 6.04]
2 Morphine positive urine or hair
analysis
6 1129 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.56, 0.78]
3 Self reported heroin use 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Criminal activity 3 363 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.12, 1.25]
5 Mortality 4 576 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.10, 2.39]
Analysis 1.1. Comparison 1 Methadone maintenance treatment vs No methadone maintenance treatment,
Outcome 1 Retention in treatment.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs No methadone maintenance treatment
Outcome: 1 Retention in treatment
Study or subgroup Methadone MT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Old studies (pre 2000)
Newman 1979 38/50 5/50 22.2 % 7.60 [ 3.26, 17.71 ]
Strain 1993a 44/84 17/81 35.2 % 2.50 [ 1.56, 3.99 ]
Vanichseni 1991 91/120 41/120 42.6 % 2.22 [ 1.70, 2.90 ]
Subtotal (95% CI) 254 251 100.0 % 3.05 [ 1.75, 5.35 ]
Total events: 173 (Methadone MT), 63 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 8.01, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 3.91 (P = 0.000092)
2 New studies
Gruber 2008 46/72 4/39 16.7 % 6.23 [ 2.42, 16.02 ]
Kinlock 2007 43/71 5/70 18.4 % 8.48 [ 3.57, 20.14 ]
Schwartz 2006 151/199 25/120 33.5 % 3.64 [ 2.55, 5.21 ]
0.002 0.1 1 10 500
Favours control Favours Methadone
(Continued . . . )
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(. . . Continued)
Study or subgroup Methadone MT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sees 2000 78/91 18/88 31.5 % 4.19 [ 2.75, 6.38 ]
Subtotal (95% CI) 433 317 100.0 % 4.44 [ 3.26, 6.04 ]
Total events: 318 (Methadone MT), 52 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.90, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 9.48 (P < 0.00001)
0.002 0.1 1 10 500
Favours control Favours Methadone
Analysis 1.2. Comparison 1 Methadone maintenance treatment vs No methadone maintenance treatment,
Outcome 2 Morphine positive urine or hair analysis.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs No methadone maintenance treatment
Outcome: 2 Morphine positive urine or hair analysis
Study or subgroup MMT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dolan 2003 39/125 43/117 13.0 % 0.85 [ 0.60, 1.21 ]
Gruber 2008 32/50 14/18 14.5 % 0.82 [ 0.60, 1.14 ]
Kinlock 2007 19/70 40/64 10.1 % 0.43 [ 0.28, 0.67 ]
Schwartz 2006 99/175 80/101 25.4 % 0.71 [ 0.61, 0.84 ]
Vanichseni 1991 70/120 109/120 25.5 % 0.64 [ 0.55, 0.75 ]
Yancovitz 1991 22/75 56/94 11.5 % 0.49 [ 0.33, 0.73 ]
Total (95% CI) 615 514 100.0 % 0.66 [ 0.56, 0.78 ]
Total events: 281 (MMT), 342 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.79, df = 5 (P = 0.06); I2 =54%
Test for overall effect: Z = 5.01 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Methadone maintenance treatment vs No methadone maintenance treatment,
Outcome 3 Self reported heroin use.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs No methadone maintenance treatment
Outcome: 3 Self reported heroin use
Study or subgroup Methadone MT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dolan 2003 41/129 92/124 0.43 [ 0.33, 0.56 ]
Dole 1969 2/12 15/15 0.20 [ 0.06, 0.61 ]
Gruber 2008 30/41 15/24 1.17 [ 0.82, 1.68 ]
Gunne 1981 5/17 12/17 0.42 [ 0.19, 0.93 ]
Kinlock 2007 28/70 39/64 0.66 [ 0.46, 0.93 ]
Yancovitz 1991 21/75 83/94 0.32 [ 0.22, 0.46 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 127 (Methadone MT), 256 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours methadone Favours control
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Analysis 1.4. Comparison 1 Methadone maintenance treatment vs No methadone maintenance treatment,
Outcome 4 Criminal activity.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs No methadone maintenance treatment
Outcome: 4 Criminal activity
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dole 1969 3/12 15/16 65.9 % 0.27 [ 0.10, 0.72 ]
Gunne 1981 0/17 2/17 13.9 % 0.20 [ 0.01, 3.88 ]
Yancovitz 1991 2/149 1/152 20.2 % 2.04 [ 0.19, 22.26 ]
Total (95% CI) 178 185 100.0 % 0.39 [ 0.12, 1.25 ]
Total events: 5 (Treatment), 18 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 2.54, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 1.59 (P = 0.11)
0.01 0.1 1 10 100
Favours methadone Favours control
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Analysis 1.5. Comparison 1 Methadone maintenance treatment vs No methadone maintenance treatment,
Outcome 5 Mortality.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs No methadone maintenance treatment
Outcome: 5 Mortality
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gunne 1981 0/17 4/17 24.0 % 0.11 [ 0.01, 1.92 ]
Kinlock 2007 0/71 1/70 20.1 % 0.33 [ 0.01, 7.93 ]
Newman 1979 3/50 1/50 34.0 % 3.00 [ 0.32, 27.87 ]
Yancovitz 1991 0/149 2/152 21.8 % 0.20 [ 0.01, 4.21 ]
Total (95% CI) 287 289 100.0 % 0.48 [ 0.10, 2.39 ]
Total events: 3 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.66; Chi2 = 3.98, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.89 (P = 0.37)
0.01 0.1 1 10 100
Favours treatment Favours control
A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials search strategy
1. OPIOID-RELATED DISORDERS*:ME
2. ((*opioid or opiate) and (*abuse or dependen* or disorder*or addict*))
3. 1 or 2
4. Heroin
5. Opioid* or Opiate*
6. #3 or #4 or #5
7. METHADONE:ME or methadone
8. (placebo or withdraw* or detox* or untreated or ”no treatment“ or ”drug free“ or ”wait list“ or waiting)
9. #6 and #7
10. #9 and #8
28Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. PubMed search strategy
1. ”substance-related disorders“ [MH]
2. ”opioid related disorders“ [MH]
3. ((*opioid OR opiate) AND (*abuse OR dependen* OR disorder* OR addict*))
4. 1 OR 2
5. Heroin [MH] OR heroin
6. Narcotics [MH]
7. opioid* OR opiate*
8. 5 OR 6 OR 7
9. 4 OR 8
10. methadone [MH] OR methadone
11. 9 AND 10
12. (placebo OR withdraw* OR detox* OR untreated OR ”no treatment“ OR ”drug free“ OR ”wait list“ OR waiting)
13. 11 AND 12
combined with the phases 1 & 2 of the Cochrane Sensitive Search Strategy for the identification of RCTs as published in Appendix
5b2, Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2006)
14. randomized controlled trial [PT]
15. randomized controlled trials [MH]
16. controlled clinical trial [PT]
17. random allocation [MH]
18. double blind method [MH]
19. single blind method [MH]
20. 14 OR 15 OR 16 OR 17 OR 18 OR 19
21. clinical trial [PT]
22. clinical trials [MH]
23. ((singl* OR doubl* OR trebl* OR tripl*) AND (blind* OR mask*))
24. PLACEBOS [MH] OR placebo*
25. random*
26. Research Design:ME
27. 14/26 OR
28. 13 AND 27
29. limit 28 to human
Appendix 3. EMBASE search strategy
1. drug abuse.me
2. Substance abuse.me
3. ((opioid or opiate) and (abuse$ or dependen$ or disorder$ or addict$))
4. 1 or 2 or 3
5. heroin.mp
6. Opiate.me or opiate$
7. opioid$
8. 5 or 6 or 7
9. 4 and 8
10. methadone.me or methadone
11. methadone treatment.me
12. 10 or 11
13. 9 and 12
14. (placebo or withdraw$ or untreated or ”drug free“ or detox$ or ”wait list“ or waiting)
15. 13 and 14
16. random$
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17. placebo$
18. (singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$))
19. crossover$
20. randomized controlled trial.me
21. phase-2-clinical-trial.me
22. phase-3-clinical-trial.me
23. double blind procedure.me
24. single blind procedure.me
25. crossover procedure.me
26. Latin square design.me
27. PLACEBOS.me
28. multicenter study.me
29. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 15 and 29
31. limit 30 to human
Appendix 4. CINAHL search strategy
1. exp ”Substance Use Disorders“/
2. ((drug or substance) and (addict* or dependen* or abuse* or disorder*))
3. 1 or 2
4. exp heroin/ or heroin
5. (opioid* or opiate*)
6. exp methadone/ or methadone
7. 3 or 4 or 5 or 6
8. (placebo or withdraw* or untreated or ”drug free“ or detox* or ”wait list“ or waiting)
9. 7 and 8
10. random*
11. (singl* or doubl* or tripl* or trebl*) and (mask* or blind*)
12. crossover*
13. allocate*
14. assign*
15. ((random*) and (allocate* or assign*))
16. exp Random Assignment/
17. exp Clinical Trials/
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 9 and 18
WH A T ’ S N E W
Last assessed as up-to-date: 18 February 2009.
Date Event Description
5 March 2009 New citation required but conclusions have not
changed
new trials included, analysis changed in respect to the
previous version, quality assessment changed following
the new rules of the Collaboration
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(Continued)
19 February 2009 New search has been performed new search, new studies found
H I S T O R Y
Protocol first published: Issue 3, 2000
Review first published: Issue 4, 2002
Date Event Description
23 February 2003 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Contributions: Richard P Mattick, Jo Klimber and Courtney Breen reviewed the papers, with Courtney Breen and Richard P. Mattick
coding data from the papers for meta-analysis.
Richard P. Mattick conceptualised the review and Courtney Breen conducted the initial literature searches.
Richard P. Mattick wrote the analysis sections and discussion. Marina Davoli was the contact editor of the review and contributed to
the writing of the final version of the review.
The review was updated by Richard P. Mattick and Courtney Breen.
D E C L A R A T I O N S O F I N T E R E S T
The first reviewer, Richard P. Mattick, is the fourth author on the Australian trial of methadone maintenance versus wait-list control
in a prison setting (Dolan 2003).
S O U R C E S O F S U P P O R T
Internal sources
• National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
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External sources
• Commonwealth Department of Health and Aged Care, Canberra, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Inactivation, Metabolic; Methadone [∗therapeutic use]; Narcotics [∗therapeutic use]; Opioid-Related Disorders [∗rehabilitation]; Ran-
domized Controlled Trials as Topic
MeSH check words
Humans
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